Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation (iSWAT)
This study is currently recruiting participants.
Verified December 2012 by University Hospital of Mont-Godinne
Sponsor:
University Hospital of Mont-Godinne
Collaborator:
Université catholique de Louvain (UCL), Institute of NeuroScience (IoNS)
Information provided by (Responsible Party):
Yves Vandermeeren, University Hospital of Mont-Godinne
ClinicalTrials.gov Identifier:
NCT01758991
First received: December 27, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the acute phase of stroke, dysphagia (difficulty/inability to swallow) is a common problem that can have serious consequences such as aspiration pneumonia, increased lenght of hospitalisation, and death. It would be interesting to enhance the therapeutic effect of swallowing retraining by means on non-invasive brain stimulation such as transcranial direct current stimulation (tDCS).
Hypothesis: during the acute phase of stroke, applying tDCS over the brain during the revalidation and/or supervised feeding improves dysphagia significantly when compared to sham tDCS.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Stroke Dysphagia |
Device: transcranial direct current stimulation (tDCS) |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Therapeutic Impact of tDCS on Dysphagia in the Acute Phase of Stroke / Impact thérapeutique de la tDCS Sur la Dysphagie en Phase Aigue de l'Accident Vasculaire cérébral |
Resource links provided by NLM:
Further study details as provided by University Hospital of Mont-Godinne:
Primary Outcome Measures:
- VideoFluoroscopy (VFSS) [ Time Frame: baseline, end of acute stroke phase, follow up (3, 6, 12 months) ] [ Designated as safety issue: No ]The patients will be asked to swallow radiocontrast agent liquid during RX (radiography) video-recording. The speed of swallowing, whether there is aspiration or stasis will be quantified off-line on videotape
- Fiberoptic Endoscopic Evaluation of Swallowing (FEES) [ Time Frame: baseline, end of acute stroke phase, follow up (3, 6, 12 months) ] [ Designated as safety issue: No ]
A laryngoscope (attached to a camera and a color monitor) will be passed through the nostril.
The patients will be asked to swallow small quantities of liquids and foods, and the quality of swallowing will be assessed off-line (videotaped examination).
The base of the tongue, pharynx and larynx will be viewed.
Secondary Outcome Measures:
- NIH Stroke Scale [ Time Frame: baseline, end of acute stroke phase, follow up (3, 6, 12 months) ] [ Designated as safety issue: No ]The NIS Stroke Scale is a clinical scale developped to score the severity of acute stroke. Patients will be asked to make some movements, vision will be tested, whether there are difficult to speak and so on.
- clinical record [ Time Frame: baseline, end of acute stroke phase, follow up (3, 6, 12 months) ] [ Designated as safety issue: No ]the records of the acute stroke patients will be used to search for relevant clinical events.
- quality-of-life (QOL) questionnaire designed for dysphagia (SWAL-QOL) [ Time Frame: baseline, end of acute stroke phase, follow up (3, 6, 12 months) ] [ Designated as safety issue: No ]A quality-of-life (QOL) questionnaire specifically designed for patients with oropharyngeal dysphagia (SWAL-QOL) will be used, questions will be asked to the patients / proxies? The French version of the SWAL-QOL will be used
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: real tDCS
patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing. tDCS will be applied during swallowing therapy, during 20 minutes |
Device: transcranial direct current stimulation (tDCS)
tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
Other Name: Eldith PLUS tDCS, NeuroConn, Ilmenau, Germany
|
|
Placebo Comparator: sham tDCS
this will be exactly as for "real tDCS" unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)
|
Device: transcranial direct current stimulation (tDCS)
tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
Other Name: Eldith PLUS tDCS, NeuroConn, Ilmenau, Germany
|
Detailed Description:
tDCS will be used in a double-blind, randomized control trial in acute stroke patients suffering from dysphagia.
After informed consent and recruitment, patients will be randomly (computer method) allocated to real or sham tDCS, that will be applied during swallowing exercices/therapy or supervised feeding.
Baseline and follow-up outcomes about dysphagia will be collected.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- acute stroke (ischemic / hemorrhagic) with dysphagia
Exclusion Criteria:
- major swallowing impairment before the stroke
- troubles of comprehension impairing communication
- major cognitive dysfunction, neuro-degenerative disease, or major psychiatric condition (e.g. depression, Alzheimer's disease, …)
- very unstable health issue (e.g. severe cardiac dyscfct, end-stage renal failure, unstable diabetes, …)
- intracranial metal and/or devices excluding tDCS application
- chronic intake of major drugs modifying brain activity (e.g. AEDs, antipsychotics)
- regular use of alcohol or recreative drugs
- epilepsy
- pregnancy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01758991
Contacts
| Contact: Katalin de Fays, BSc | +32 81 42 33 48 | katalin.defays@uclouvain.be |
Locations
| Belgium | |
| University Hospital of Mont-Godinne : CHU Mont-Godinne UCL | Recruiting |
| Yvoir, Namur, Belgium, 5530 | |
| Contact: Katalin de Fays, MSc +3281423348 katalin.defays@uclouvain.be | |
Sponsors and Collaborators
University Hospital of Mont-Godinne
Université catholique de Louvain (UCL), Institute of NeuroScience (IoNS)
Investigators
| Principal Investigator: | Yves Vandermeeren, MD, PhD | University Hospital of Mont-Godinne |
More Information
Additional Information:
No publications provided
| Responsible Party: | Yves Vandermeeren, Professor (MD, PhD), University Hospital of Mont-Godinne |
| ClinicalTrials.gov Identifier: | NCT01758991 History of Changes |
| Other Study ID Numbers: | B039201111926 |
| Study First Received: | December 27, 2012 |
| Last Updated: | December 27, 2012 |
| Health Authority: | Belgium: Ethics Committee Belgium: Institutional Review Board |
Additional relevant MeSH terms:
|
Deglutition Disorders Stroke Cerebral Infarction Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Pharyngeal Diseases Otorhinolaryngologic Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction Brain Ischemia |
ClinicalTrials.gov processed this record on May 16, 2013